

of the cases and all of the electrocardiograms were normal.⁴ There have been 2 reported cases of infants who experienced an apparent life-threatening event attributed to long QT syndrome, and there is 1 reported case of an infant with Brugada syndrome who experienced an apparent life-threatening event associated with ventricular fibrillation, but his QT interval was normal.^{5,6} Hence, considering the rarity of apparent life-threatening events caused by long QT syndrome or short QT syndrome, there has not been any formal recommendation that all infants experiencing an apparent life-threatening event should have electrocardiography as part of the clinical evaluation following the event, except insofar as indicated by the baby's specific history and initial clinical evaluation. Although again this is outside the scope of our review, we would agree with this general approach.

Carl E. Hunt

Department of Pediatrics
Uniformed Services University of the
Health Sciences
Bethesda, Md.

Fern R. Hauck

Departments of Family Medicine and
Public Health Sciences
University of Virginia
Charlottesville, Va.

REFERENCES

- Hunt CE, Hauck FR. Sudden infant death syndrome. *CMAJ* 2006;174(13):1861-9.
- Zupancic JAF, Triedman JK, Alexander M, et al. Cost-effectiveness and implications of newborn screening for prolongation of QT interval for the prevention of sudden infant death syndrome. *J Pediatr* 2000;136:481-9.
- Giustetto C, Di Monte F, Wolpert C, et al. Short QT syndrome: clinical findings and diagnostic-therapeutic implications. *Eur Heart J* 2006;27:2440-7.
- Brand DA, Altman RL, Purtil K, et al. Yield of diagnostic testing in infants who have had an apparent life-threatening event. *Pediatrics* 2005;115:885-93.
- Skinner JR, Chung S-K, Montgomery D, et al. Near-miss SIDS due to Brugada syndrome. *Arch Dis Child* 2005;90:528-9.
- Schwartz PJ, Priori SG, Dumaine R, et al. A molecular link between the sudden infant death syndrome and the long QT syndrome. *N Engl J Med* 2000;343:262-7.

DOI:10.1503/cmaj.1070016

Clarification of the CMA's position concerning induced abortion

A recent editorial in *CMAJ*¹ and subsequent letters to the editor have raised several questions about the Canadian Medical Association's position on induced abortion. I would like to clarify that position with this illustrative case.

Case: You are a family physician practising at a community health care centre. A 25-year-old patient recently had a positive pregnancy test and estimates that she is 7 weeks' pregnant. She asks if you will perform a therapeutic abortion. If not, will you refer her right away to someone who will perform it? You are morally opposed to abortion. What are your obligations to this patient?

Discussion: CMA policy² states that "a physician should not be compelled to participate in the termination of a pregnancy." In addition, "a physician whose moral or religious beliefs prevent him or her from recommending or performing an abortion should inform the patient of this so that she may consult another physician."

You should therefore advise the patient that you do not provide abortion services. You should also indicate that because of your moral beliefs, you will not initiate a referral to another physician who is willing to provide this service (unless there is an emergency).

However, you should not interfere in any way with this patient's right to obtain the abortion. At the patient's request, you should also indicate alternative sources where she might obtain a referral. This is in keeping with the obligation spelled out in the CMA policy: "There should be no delay in the provision of abortion services."

Jeff Blackmer

Executive Director, Office of Ethics
Canadian Medical Association
Ottawa, Ont.

REFERENCES

- Rodgers S, Downie J. Abortion: ensuring access [editorial]. *CMAJ* 2006;175(1):9.
- Induced abortion* [CMA policy]. Ottawa (ON): Canadian Medical Association; 1988.

DOI:10.1503/cmaj.1070035

Editor's note: We received a large number of letters in response to the editorial by Rodgers and Downie, with particular regard to the CMA's policy on induced abortion. We asked the CMA to assist our readers by clarifying their position using a case-based example, which they have provided here. We will not publish any further letters on this topic, unless they present new information or state a new position on this matter.

Corrections

In the supplement to the March 13 issue of *CMAJ*,¹ the term "neuropathy" was omitted from a list that appears on page 15 under the heading "Diabetes-related vasculopathy" and the subheading "Microvasculature." That list should have read as follows: retinopathy, nephropathy, neuropathy.

REFERENCE

- Pilote L, Dasgupta K, Guru V, et al. A comprehensive view of sex-specific issues related to cardiovascular disease. *CMAJ* 2007;176(Suppl):S1-44.

DOI:10.1503/cmaj.070432

A recent News article¹ contained an error concerning the vaccine that GlaxoSmithKline is developing. The sentence "GlaxoSmithKline's Cervarix will block HPV strains linked to 80% of cervical cancers" should have read as follows: "GlaxoSmithKline's Cervarix may block HPV strains linked to 80% of cervical cancers." We apologize for any inconvenience this error may have caused.

REFERENCE

- Comeau P. Debate begins over public funding for HPV vaccine. *CMAJ* 2007;176(7):913-4.

DOI:10.1503/cmaj.070433